Glucose News and Research

RSS

New molecular imaging technique raises hope for common malignant female tumor

A promising new molecular imaging technique may provide physicians and patients with a noninvasive way to learn more information about a type of cancer of the uterus lining called "endometrial carcinoma"-one of the most common malignant female tumors. This research was presented in a study published in the October issue of The Journal of Nuclear Medicine.

1 Oct 2009

Screening and diagnostic tests contribute to health care value across spectrum of care

Amidst ongoing debate in Congress over reforming the nation's health care system, a new report from the Lewin Group finds that screening and diagnostic laboratory tests are central to achieving some of the most important goals of health care reform.

1 Oct 2009

Treating mothers for mild gestational diabetes reduces infant deaths and birth-related complications

Treating pregnant women for mild gestational diabetes resulted in fewer cesarean sections and other serious birthing problems associated with larger than average babies, according to a study conducted in part at the University of North Carolina at Chapel Hill.

1 Oct 2009

Treatment of gestational diabetes benefits both infant and mother

A National Institutes of Health network study provided the first conclusive evidence that treating pregnant women who have even the mildest form of gestational diabetes can reduce the risk of common birth complications among infants, as well as blood pressure disorders among mothers.

1 Oct 2009

Annual campaign to help patients learn about, manage and prevent diabetes

Rite Aid has kicked off its annual campaign on diabetes management by supporting the American Diabetes Association, the leading diabetes voluntary health organization, and dLife, the leading online diabetes resource, in the fight to stop diabetes.

1 Oct 2009

SFC Fluidics to develop handheld traumatic brain injury diagnostic device for the U.S. Army

SFC Fluidics, LLC recently announced it has received a contract for approximately $5 million from the Congressionally Directed Medical Research Program for development of a handheld device for rapid diagnosis of traumatic brain injury (TBI). More than 1.5 million Americans suffer head injuries each year, and TBI has become a signature injury for American troops serving in the wars in Iraq and Afghanistan.

30 Sep 2009

Genetic factors play an important role in the development of type 1 diabetes

Under the direction of Prof. Dr. Anette Ziegler, scientists of the Diabetes Research Group at Helmholtz Zentrum München and Technische Universität München investigated the formation of antibodies to a zinc transporter in children with elevated risk for type 1 diabetes. The study provided indications of an early onset of the disease when specific antibodies in the blood and specific variants of the associated zinc transporter are present in the genome.

30 Sep 2009

VeriChip and Optimus sign definitive agreement

VeriChip Corporation ("VeriChip" or the "Company") today announced it has entered into a definitive agreement for a $10,000,000 investment commitment with Optimus Technology Capital Partners, LLC, or Optimus.

30 Sep 2009

AFRESA Inhalation Powder and AFRESA Inhaler NDA under FDA review

AFRESA® (insulin human [rDNA origin]) Inhalation Powder is a well-tolerated, ultra rapid acting insulin able to more closely replicate normal glucose suppression than currently available insulins, according to data presented at the 45th Annual Meeting of the European Association for the Study of Diabetes.

30 Sep 2009

Diabetics should monitor their blood sugar levels to improve metabolic status

Diabetes patients should always control their own blood sugar values if this leads to improvements in their treatment. This is the view advocated by Michael Nauck of the Bad Lauterberg Diabetes Center and his coauthors in the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2009; 106[37]: 587-94), who discuss sensible approaches to blood glucose self-monitoring.

29 Sep 2009

Januvia in combination with metformin or taken alone lowers blood sugar

A post-hoc analysis, presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD), of data pooled from studies of 104 weeks in duration showed ‘Januvia’ (sitagliptin), when taken alone or in combination with metformin, provided significant blood sugar lowering over two years.

29 Sep 2009

Biochemistry professor to discuss controversies in dietary strategies in diabetes treatment

Richard Feinman, PhD, professor of biochemistry and of family medicine at SUNY Downstate Medical Center in Brooklyn, New York, will speak at the annual conference of the European Association for the Study of Diabetes (EASD) on October 2, 2009. EASD is holding its annual conference September 28 - October 2 in Vienna, Austria.

29 Sep 2009

GlobalData's report on the diabetes care device market

MarketResearch.com has announced the addition of GlobalData's new report "Global Diabetes Care Devices Market Analysis and Forecasts to 2015," to their collection of Medical Device market reports.

29 Sep 2009

Halozyme Therapeutics announces Phase 1 clinical study to assess three insulin analogs

Halozyme Therapeutics, Inc. today announced the commencement of a Phase 1 clinical study that will assess the effects of three approved prandial (mealtime) insulin analogs administered with its proprietary rHuPH20 (PH20) hyaluronidase enzyme compared to each of the analogs alone. This randomized, three-way cross-over design, euglycemic clamp study will compare the postprandial pharmacokinetics (PK) and glucodynamics (GD) of the insulin analogs.

28 Sep 2009

Diabetic hypoglycemia remains a critical concern in young patients

A recent Lancet article predicted a doubling of new cases of type 1 diabetes in European children aged under 5, and a 70% rise in cases in children under 15 years - an incidence rate exceeding all previous predictions. Studies in the USA and other countries also suggest similar trends.

28 Sep 2009

Increasing insulin levels can aid muscle building in the elderly

Recently, scientists have recognized that loss of responsiveness to insulin plays a major role in the loss of physical strength that occurs as people grow older. Now, University of Texas Medical Branch at Galveston researchers have demonstrated that by increasing insulin levels above the normal range in elderly test subjects, they can restore the impaired muscle-building process responsible for age-related physical weakness.

28 Sep 2009

Rosiglitazone slows progression of cachexia in cancer affected mice

Insulin resistance, the hallmark of type 2 diabetes and a condition often associated with obesity, is paradoxically also an apparent contributor to muscle wasting and severe fat loss that accompanies some cancers, according to new research.

27 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009

TRUEresult store brand blood glucose monitoring system more accurate than name brand products: Study

Home Diagnostics, Inc., a leading manufacturer and marketer of diabetes testing supplies, today announced that a new study has shown that its TRUEresult® store brand blood glucose monitoring system is comparable to the performance of more expensive name brand systems.

24 Sep 2009

Study reveals that AIR Inhaled Insulin is inferior to SC insulin

The commercial failure of Exubera- (Pfizer, New York, NY), the first inhaled insulin product to come to market, led other companies such as Eli Lilly-Alkermes to halt studies of similar drug delivery in development intended to compete for a share of the lucrative diabetes market. Does this signal defeat for efforts to deliver insulin via the lungs? The science and circumstances behind the Lilly-Alkermes decision to discontinue trials of the AIR- inhaled insulin product are explored in a special supplement to Diabetes Technology & Therapeutics, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The supplement is available free online at www.liebertpub.com/dia

24 Sep 2009